Cerebral Atherosclerosis
Conditions
Keywords
atherosclerosis, plaque burden, Evolocumab, High-Resolution assessment, OCT
Brief summary
This study intends to explore the therapeutic effect of PCSK9i Evolocumab on atherosclerotic plaques in cerebral arteries (including carotid and vertebral arteries) compared with intensive statin treatment, and monitor the pathological properties of carotid/vertebral artery plaques with OCT technology. At the same time, three-dimensional ultrasound and high-resolution magnetic resonance are used to explore the new mechanism of pathological changes of cerebral atherosclerotic plaques in a multidimensional manner.
Interventions
Evolocumab 140mg, subcutaneous injection, every 2 weeks, for 26 week, total 13 times
Intensive statin could choose either Atorvastatin 40mg/day or Rosuvastatin 20mg/day, for 26 weeks
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years old, regardless of sex; 2. Cerebrovascular angiography examination was performed, and the imaging characteristics were consistent with: 1) The stenosis degree of internal carotid artery (starting from C1 segment) or vertebral artery (starting from vertebral artery to V4 segment) was 20%-69%; 2) The target vessel for imaging has not undergone or intends to undergo revascularization and must be available for OCT imaging catheter; 3. Participants who understand and sign the informed consent form voluntarily.
Exclusion criteria
1. Intolerant to both atorvastatin and rosuvastatin; 2. History of major surgery or endovascular treatment within 3 months prior to the screening period; 3. Arterial stenosis or occlusion not caused by atherosclerosis, such as arterial dissection, moya-moya disease, vasculitis, radiation vascular disease, or fibromuscular dysplasia; 4. Abnormal liver function (ALT \> 3 times the upper limit of normal); 5. Renal dysfunction (glomerular filtration rate (eGFR) \<45 mL/min/1.73m2 at screening); 6. Thrombocytopenia (PLT\<100G/L); 7. The expected survival time is not more than 6 months; 8. Other known serious life-threatening disease (such as hematologic disease, malignancy), unstable vital signs or need for continuous monitoring, or moribund state during screening; 9. Patients have been included in other studies that conflict with this study; 10. Known sensitivity to any of the products or components to be administered during dosing; 11. Pregnant, breastfeeding or planning pregnancy, and other conditions that the investigator considers the patient unsuitable for enrollment; 12. Other conditions that the investigator considered inappropriate for enrollment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes of the thickness of fibrous cap of artery plaque measured by OCT | 27 Weeks ± 7 days | Changes of the thickness of fibrous cap of artery plaque measured by OCT |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes of the lipid arc of artery plaque measured by OCT | 27 Weeks ± 7 days | Changes of the lipid arc of artery plaque measured by OCT |
| Changes of the minimum lumen area (MLA) measured by OCT | 27 Weeks ± 7 days | Changes of the minimum lumen area (MLA) measured by OCT |
| Changes of lumen area stenosis measured by OCT | 27 Weeks ± 7 days | Changes of lumen area stenosis measured by OCT |
| Changes of the number of microvessels measured by OCT | 27 Weeks ± 7 days | Changes of the number of microvessels measured by OCT |
| Changes of the presence and extension of macrophages measured by OCT | 27 Weeks ± 7 days | Changes of the presence and extension of macrophages measured by OCT |
| Changes of the calcium aggregation measured by OCT | 27 Weeks ± 7 days | Changes of the calcium aggregation measured by OCT |
| Changes of arterial plaque volume measured by OCT | 27 Weeks ± 7 days | Changes of arterial plaque volume measured by OCT |
| Changes of lipid necrotic core of arterial plaque measured by OCT | 27 Weeks ± 7 days | Changes of lipid necrotic core of arterial plaque measured by OCT |
| Changes of Lipid necrotic core of arterial plaque measured by High resolution magnetic resonance | 27 Weeks ± 7 days | Changes of Lipid necrotic core of arterial plaque measured by High resolution magnetic resonance |
| Correlation between arterial plaque and new risk factors for cardiovascular and cerebrovascular diseases (serum hsCRP, other markers, etc.) | 27 Weeks ± 7 days | Correlation between arterial plaque and new risk factors for cardiovascular and cerebrovascular diseases (serum hsCRP, other markers, etc.) |
| Changes of LDL-C levels | 27 Weeks ± 7 days | Changes of LDL-C levels |
| Changes of the thickness of minimum fibrous cap of artery plaque measured by 3D-ultrasound | 27 Weeks ± 7 days | Changes of the thickness of minimum fibrous cap of artery plaque measured by 3D-ultrasound |
| Changes of arterial plaque volume measured by 3D-ultrasound | 27 Weeks ± 7 days | Changes of arterial plaque volume measured by 3D-ultrasound |
| Changes of Lipid necrotic core of arterial plaque measured by 3D-ultrasound | 27 Weeks ± 7 days | Changes of Lipid necrotic core of arterial plaque measured by 3D-ultrasound |
| Changes of the thickness of minimum fibrous cap of artery plaque measured by High resolution magnetic resonance | 27 Weeks ± 7 days | Changes of the thickness of minimum fibrous cap of artery plaque measured by High resolution magnetic resonance |
| Changes of arterial plaque volume measured by High resolution magnetic resonance | 27 Weeks ± 7 days | Changes of arterial plaque volume measured by High resolution magnetic resonance |
Other
| Measure | Time frame | Description |
|---|---|---|
| Occurrence of ischemic vascular events | 27 Weeks ± 7 days | Occurrence of ischemic vascular events, such as TIA, acute cerebral infarction, acute myocardial infarction, etc. |
| Adverse events/serious adverse events | through study completion, an average of 6 months | Adverse events/serious adverse events |
Countries
China
Contacts
Primary ContactYan Wan, Doctor
Backup ContactShengcai Chen, Doctor
Outcome results
None listed